Clinical Trials · NCT06650579
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Emory University
- Enrollment
- 72
- Start date
- Jan 2025
- Locations
- 4 sites, United States
- Primary endpoint
- Incidence of ambulatory systolic blood pressure (BP) > 140 or diastolic > 90 (measurement on 2 separate days)